Srinivas Akkaraju, Director at CHINOOK THERAPEUTICS, INC. (KDNY), bought 570,000 shares at $14.00 ($8.0M) on 2022-05-27, disclosed to the SEC on 2022-06-01.
Open-market purchase of $8.0M KDNY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| KLRS | BUY | 2026-05-22 | $1.2M | — | Filing → |
| ALMS | BUY | 2026-01-13 | $10.0M | — | Filing → |
| SRRK | BUY | 2025-12-16 | $1.9M | — | Filing → |